MedPath

Adaptimmune Therapeutics

🇬🇧United Kingdom
Ownership
Public
Employees
449
Market Cap
$317.1M
Website
http://www.adaptimmune.com
Introduction

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

onclive.com
·

FDA Approval Insights: Afami-Cel for Pretreated, Unresectable or Metastatic Synovial Sarcoma

OncLive On Air podcast discusses FDA approval of afamitresgene autoleucel (afami-cel) for advanced synovial sarcoma, supported by Adaptimmune Therapeutics. Dr. Allison Betof Warner, Stanford University, highlights SPEARHEAD-1 trial results and multidisciplinary collaboration in cell therapy administration.
cgtlive.com
·

FDA Activity Recap: August 2024 Features TCR T-Cell Therapy Approval, REMS

In August 2024, the FDA approved Adaptimmune Therapeutics’ afami-cel for synovial sarcoma, modified REMS for CAR-T therapies, lifted a hold on 4D Molecular Therapeutics’ Fabry disease gene therapy, provided guidance for IN8bio’s INB-100 in AML, and cleared Biosyngen’s BRG01 for a pivotal trial in EBV-positive nasopharyngeal carcinoma.
drugs.com
·

FDA Grants Accelerated Approval for Tecelra (afamitresgene autoleucel) Cell Therapy for the Treatment of Synovial Sarcoma

FDA grants accelerated approval for Tecelra (afamitresgene autoleucel) cell therapy for treating adults with unresectable or metastatic synovial sarcoma who have received prior chemotherapy and meet specific HLA and MAGE-A4 antigen criteria. This marks the first engineered cell therapy for a solid tumor cancer approved in the U.S. and the first new therapy option in over a decade for synovial sarcoma.
© Copyright 2025. All Rights Reserved by MedPath